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Abstract Microglial cells are the primary immune effector
cells in the brain. Extracellular ATP, e.g., released after brain
injury, may initiate microglial activation via stimulation of
purinergic receptors. In the rat nucleus accumbens (NAc), the
involvement of P2X and P2Y receptors in the generation of
microglial reaction in vivo was investigated. A stab wound in
the NAc increased immunoreactivity (IR) for P2X1,2,4,7 and
P2Y1,2,4,6,12 receptors on microglial cells when visualized
with confocal laser scanning microscopy. A prominent im-
munolabeling of P2X7 receptors with antibodies directed
against the ecto- or endodomain was found on Griffonia
simplicifolia isolectin-B4-positive cells. Additionally, the
P2X7 receptor was colocalized with active caspase 3 but not
with the anti-apoptotic marker pAkt. Four days after local
application of the agonists α,βmeATP, ADPβS, 2MeSATP,
and BzATP, an increase in OX 42- and G. simplicifolia
isolectin-IR was observed around the stab wound, quantified
both densitometrically and by counting the number of ram-
ifiedandactivatedmicroglialcells,whereasUTPγSappeared
to be ineffective. The P2 receptor antagonists PPADS and
BBG decreased the injury-induced increase of these IRs
when given alone and in addition inhibited the agonist ef-
fects. Further, the intra-accumbally applied P2X7 receptor
agonist BzATP induced an increase in the number of caspase-
3-positive cells. These results indicate that ATP, acting via
different P2X and P2Y receptors, is a signaling molecule
in microglial cell activation after injury in vivo. The up-
regulation of P2X7-IR after injury suggests that this receptor is
involved in apoptotic rather than proliferative effects.
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Abbreviations
ATP adenosine 5′-triphosphate
α,βmeATP α,βmethyleneATP
ACSF artificial cerebrospinal fluid
ADPβS adenosine 5′-(β-thio)diphosphate
BBG brilliant blue G
BrdU 5-bromo-2′-deoxyuridine
BzATP 2′,3′-O-(4-benzoyl-benzoyl)ATP
BSI-B4 lectin from Bandeiraea simplicifolia
(Griffonia simplicifolia) isolectin B4
(peroxidase-labeled)
GFAP glial fibrillary acidic protein
GSA-B4 lectin from Bandeiraea simplicifolia
(Griffonia simplicifolia) isolectin B4
(biotin-conjugated)
2MeSATP 2-methylthioATP
IR immunoreactivity
NAc nucleus accumbens
pAkt phosphorylated serine/threonine kinases
PPADS pyridoxal-5′-phosphate-6-azophenyl-2′,4′-
disulphonic acid
RT-PCR reverse transcription polymerase chain
reaction
UTPγS uridine 5′-O-(γ-thio)triphosphate
Introduction
Microglialcells aretheprincipalintrinsicimmune competent
cells of the brain. Resting microglial cells with a ramified
morphology become activated under almost all pathological
conditions, e.g., mechanical or chemical injury or inflam-
mation. They change into ameboid-shaped motile phagocy-
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e-mail: frah@medizin.uni-leipzig.detotic and cytotoxic cells, which invade the site of injury and
initiate repair or defense processes by secreting proteases,
neurotrophic factors, and inflammatory mediators [1, 2].
This suggests that microglial cells are able to sense signal
molecules entering the extracellular space by disturbances
of brain homeostasis and promoting their transformation
into the active state [3, 4]. Further, microglia express major
histocompatibility complex antigen class II and may
perform phagocytotic activity to clear cellular debris [4–7].
One of the most prominent compounds released by injury
is the purine nucleotide ATP. Extracellularly applied ATP
induces the activation of a cation conductance and a sub-
sequent increase in intracellular Ca
2+ [8]. ATP was shown to
stimulatemicroglialcellstorespondwithrapidmovementsof
their processes [9]. Further, ATP also induced the outgrowth
of processes and membrane ruffling in cultured systems [10,
11]. Dependent on the concentration of ATP applied to in
vitro systems, microglial cells secrete various biologically
active substances, such as the cytokines tumor necrosis fac-
tor-α (TNF-α)[ 12], interleukin (IL)-1β [13, 14], or IL-6
[15]. Boucsein and colleagues [16] have shown that in the
presence of purinergic ligands, the lipopolysaccharide-induced
release of TNF-α, IL-6, IL-12, and macrophage inflammatory
protein-1α was attenuated. In patch-clamp investigations with
ATP-induced Ca
2+ wave recordings of astrocytes, a current
response in an adjacent microglial cell was observed, sug-
gesting that microglia can sense the activity of astrocytes [17].
All these data suggest that a variety of ATP-sensitive iono-
tropic(P2X) andmetabotropic(P2Y)receptors isexpressedat
resting and/or activated microglial cells [18–22]. The func-
tional expression of ATP receptors on cultured microglia is
well known [18, 23, 24]. The basic problem in studying this
type of glial cells is that any manipulation ex vivo or in vitro
will promote their transformation into the active form. We
usedaninvivomodelofastabwoundinjuryintheratnucleus
accumbens (NAc) to observe the P2 receptor-mediated re-
sponse of microglial cells to ATP released by injury. This
technique enables local administration of receptor-specific
purinergic ligands by microinfusion. Furthermore, our inves-
tigations focused especially on the P2X7 receptor subtype on
microglial cells in vivo and the functional consequences of
injury-induced stimulation. The possible involvement of
P2X7 receptors in apoptotic and proliferative processes in
microglia and astrocytes, respectively, was also investigated.
Material and methods
Materials
Ketamine hydrochloride (Ketanest; Ratiopharm, Ulm, Ger-
many), xylazine hydrochloride (Rompun; Bayer, Leverkusen,
Germany), and thiopental natrium (Trapanal, Altana Pharma,
Konstanz, Germany) were used for anesthesia. For intra-
accumbal microinjection, 2-methylthioATP (2MeSATP),
α,β-methyleneATP (α,βmeATP, both RBI; Natick, MA,
USA); adenosine 5′-(β-thio)diphosphate (ADPβS), 2′,3′-O-
(4-benzoyl-benzoyl)ATP (BzATP), brilliant blue G (BBG),
and 5-bromo-2′-deoxyuridine (BrdU) (all from Sigma, Dei-
senhofen, Germany); uridine 5′-O-(γ-thio)triphosphate
(UTPγS, Inspire Pharmaceuticals Inc., Durham, NC, USA);
pyridoxal-5′-phosphate-6-azophenyl-2′,4′-disulphonic acid
(PPADS; Biotrend, Köln, Germany); and artificial cerebrospi-
nal fluid [ACSF (in mM): 126 NaCl; 2.5 KCl; 1.2 NaH2PO4;
1.3 MgCl2, and 2.4 CaCl2;p H7 . 4 ]w e r eu s e d .
Antibodies directed against glial fibrillary acidic protein
(GFAP; mouse anti-GFAP, Sigma, Deisenhofen, Germany;
rabbit anti-cow GFAP, DakoCytomation, Hamburg, Ger-
many); BrdU (mouse anti-BrdU, Clone Bu20a; DakoCyto-
mation), active caspase 3 (rabbit, Promega, Madison, WI,
USA); OX 42 (CD 11b, mouse anti-rat, complement receptor
type 3; Serotec, Oxford, UK); (a) lectin from Bandeiraea
simplicifolia (Griffonia simplicifolia) isolectin B4 (BSI-B4,
peroxidase labeled) and (b) lectin from B. simplicifolia (G.
simplicifolia) isolectin B4 (GSA-B4, biotin conjugated;
Sigma, Deisenhofen, Germany, each); phosphorylated ser-
ine/threonine kinases (pAkt1/2/3; rabbit, Ser 473, raised
against the short amino acid sequence containing phosphor-
ylated Ser 473 of Akt 1, Akt 2, and Akt 3 of mouse origin,
recommended for the detection of Ser 473 phosphorylated
Akt 1 and corresponding phosphorylated Akt 2 and Akt 3
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA); and
the following P2 receptor antisera were used: rabbit anti-
P2X1,a n t i - P 2 X 2, and anti-P2X4,5,6 (Alomone Labs, Jerusa-
lem, Israel) as well as rabbit anti-P2X7 receptor-subtype
(intracellular C-terminus binding, Alomone Labs), anti-P2X3
(guinea pig; Neuromics Inc., Northfield, MN, USA). Further-
more, a goat anti-rat ecto-P2X7 receptor antibody (a kind gift
o fD r .M .K i m ;[ 25]) was used for immunofluorescence
double-labeling studies. Additionally, anti-P2Y1, anti-P2Y2,
anti-P2Y4, anti-P2Y12 (rabbit; Alomone Labs, Jerusalem,
Israel), anti-P2Y6 (rabbit; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and anti-P2Y1 (rabbit, GlaxoSmithKline,
Brentford, Middlesex, UK) receptor antibodies were tested.
The secondary carbocyanine (Cy)2- and Cy3-conjugated IgGs
as well as Cy2- and Cy3-conjugated streptavidin (Jackson
ImmunoResearch, West Grove, PA, USA) were used. For
histochemical detection, 3,3′-diaminobenzidine hydrochloride
(DAB; Sigma Chemical Co., St. Louis, USA) was applied.
Animals
Male Wistar rats (280–320 g) were housed under a 12-h light,
12 h-dark cycle and allowed access to lab food and water ad
libitum. All procedures using animals were approved by the
committee of Animal Care and Use of the relevant local
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mental animal protection.
Surgery/microinjection
Anesthetized rats were fixed in a stereotaxic frame. At the
coordinates AP=1.7 mm (rostral to bregma), L=1.5 mm
(lateral to the sagittal suture), and V=6.5 mm (below the
surface of the hemisphere), the injection cannulae connec-
ted to a syringe pump via an FEP tubing was inserted into
the NAc [26]. By microinfusion, rats received ACSF, which
was used as control as well as vehicle for the following P2
receptor agonists: 2MeSATP (nonselective), α,βmeATP
(P2X1,3), ADPβS (P2Y1,11,12,13), UTPγS (P2Y4,6), given
as 0.1 nmol each, and BzATP (preferential P2X7) 0.3 nmol.
As antagonists, PPADS (30 pmol; nonselective) and BBG
(1 pmol, P2X7) were applied. When the effects of the P2
receptor agonists were pharmacologically proven, the micro-
infusionoftherespectiveantagonistsprecededinfusionofthe
agonist and antagonist mixture. As a proliferation marker,
BrdU(0.1nmol)wasappliedtogetherwiththeantagonist,the
agonist, or ACSF alone. Test substances were injected in a
volume of 1 μla tar a t eo f1 2μl/h.
Immunocytochemical studies and double-
immunofluorescence studies
Immunocytochemical and double-immunofluorescence stud-
ies were done as previously described [26, 27]. After a
postinjection time of 2 h and 4 days, the rats were transcar-
dially perfused under thiopental sodium anesthesia with
paraformaldehyde (2%) in sodium acetate buffer (pH 6.5;
solution A) followed by paraformaldehyde (2%)/glutaralde-
hyde (0.1%) in sodium borate buffer (pH 8.5; solution B).
The brains were immediately removed and stored overnight
in solution B without glutaraldehyde. Serial coronal sections
(50-μm thick) from the NAc were obtained using a vibra-
tome (Leica, Typ VT 1000S, Nussloch, Germany) and col-
lected as free-floating slices (0.1 M Tris; pH 7.6).
Immunocytochemical studies
BSI immunoreactivity
Free-floating sections were rinsed with 0.05 M Tris-buffered
saline (TBS, pH 7.6) and were treated with 1% hydrogen
peroxide for 30 min to inactivate endogenous peroxide
activity. Immunolabeling was performed with lectin from
BSI-B4(1:200) in TBScontaining2% bovine serum albumin
overnight at 4°C, followed by washing in 0.05 M Tris buffer
(pH 8.0). Peroxidase activity was visualized with DAB
(0.07%) containing nickel ammonium sulphate (1%) and
hydrogen peroxide, which renders a black reaction product.
Active caspase 3 immunoreactivity
Free-floating sections were rinsed with 0.1 M TBS (pH 7.4)
and treated with 1% hydrogen peroxide for 25 min to inac-
tivate endogenous peroxide activity. Immunoreactivity (IR)
was studied with rabbit anti-active caspase 3 (1:500) in TBS
containing 10% normal horse serum (NHS) and 0.1% Triton
X-100 overnight at 4°C, followed by biotinylated horse anti-
rabbit IgG (1:100, Vector Labs. Burlingame, CA, USA) and
preformed streptavidin/biotin-peroxidase complex (1:125,
StreptABComplex; DakoCytomation) for 2 h. DAB (0.05%)
served as chromogen.
GFAP/BrdU immunoreactivity
The procedure was applied to free-floating slices as previ-
ously described [26]. Briefly, the GFAP staining procedure
was carried out with rabbit anti-cow GFAP antiserum
(1:600) and biotinylated protein A (1:400; Calbiochem, La
Jolla, CA, USA). To detect the astroglial marker, the
streptavidin/biotin technique based on a StreptABComplex
(1:125) and DAB (0.05%) as chromogen were used. Mitotic
astrocytes were identified by immunostaining of the incor-
porated BrdU. After DNA denaturation (2 N HCl) and neu-
tralization (borate buffer; 0.15 M; pH 8.5), the slices were
incubated with a mouse monoclonal antibody against BrdU
(1:75), followed by incubation with horse biotinylated anti-
mouse immunoglobulins (1:100; Vector Labs., Burlingame,
CA, USA) and with ABC Elite Kit (1:50; Vectastain; Vector).
Peroxidase activity was visualized with DAB (0.07%)
containing nickel ammonium sulphate (1%) plus cobalt
chloride (1%) (DAB-Ni/Co) and hydrogen peroxide, which
renders a black reaction product. For GFAP/BrdU double-
stainingexperiments tocharacterizemitogenic changes,slices
werefirstprocessedforanti-GFAPlabelingfollowedbyBrdU
immunolabeling.
Double-immunofluorescence studies
After washing with TBS (0.05 M; pH 7.6) and blocking with
normal goat serum (1% NGS) in TBS, slices were incubated
in an antibody mixture of mouse anti-OX 42 (CD11b; 1:100)
and rabbit anti-P2X receptor antibodies (P2X1 1:400; P2X2
1:400; P2X4 1:400; P2X5 1:400; P2X6 1:400; P2X7 1:1,000)
or P2Y receptor antibodies [P2Y1 1:400; P2Y2 1:1,000;
P2Y4 1:1,000; P2Y12 1:400 (Alomone Labs); P2Y1: 1:1,500
(GlaxoSmithKline); P2Y6 1:200 (Santa Cruz Biotechnology,
Inc.)] with 0.1% Triton X-100 in 1% NGS in TBS for 48 h at
4°C. The secondary antibodies employed for simultaneous
localization of the two primary antisera were Cy2-conjugated
goat anti-mouse IgG (1:500) and Cy3-conjugated goat anti-
rabbit IgG (1:800), respectively. Cy2-conjugated goat anti-
guinea pig IgG (1:400) and Cy3-conjugated goat anti-mouse
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P2X3 (1:1,000). Sections were washed three times for 5 min
each in 1% NGS [or 5% fetal calf serum (FCS) for guinea
pig anti-P2X3] in TBS and then incubated for 2 h in a
solution containing a mixture of the secondary antibodies
with 1% NGS (5% FCS) in TBS.
GSA-B4 and P2X or P2Y double labeling was performed
in two steps: first the incubation of the slices with GSA-B4
(1:300), followed by treatment with Cy2-conjugated strepta-
vidin (1:350); and second, by incubation with rabbit P2X/Y
antibodies followed by Cy3-conjugated goat anti-rabbit IgG
(1:800) as described above. The ecto-P2X7 receptor antibody
(goat anti-rat ecto-P2X7 receptor, 0.12 μg/ml [25]) was
combined with rabbit anti-caspase 3 (1:500), rabbit anti-pAkt
(1:600), or rabbit anti-P2X7 (C-terminal, 1:1,000) and subse-
quent detection with Cy2-conjugated donkey anti-goat IgG
(1:1,000) and Cy3-donkey anti-rabbit IgG (1:1,000). Incu-
bation of slices with goat anti-rat ecto-P2X7 (1:600), rabbit
anti-active caspase 3 (1:500), or rabbit anti-pAkt (1:600) and
GSA-B4 (1:300) was followed by treatment with Cy3-
conjugated donkey anti-goat (1:1,000) or Cy3-conjugated
goat anti-rabbit IgG (1:400) and Cy2-conjugated streptavidin
(1:350). Control experiments were carried out without the
primary P2 receptor antibody or by preadsorption of the anti-
body with the peptides used for their generation. When slices
were incubated with PBS instead of the primary antibody or
with primary antibody serum, which had been preabsorbed
with peptide antigen for 1 h before use, no immunofluores-
cence with either of the control procedures was observed.
After intensive washing and mounting on glass slides, all
stainedsectionswere dehydratedina seriesofgradedethanol,
processed through n-butylacetate, coverslipped with entellan
(Merck, Darmstadt, Germany), and analyzed by light micros-
copy or confocal laser scanning microscopy.
Confocal microscopy
Double immunofluorescence was investigated by a scanning
confocal microscope (LSM 510, Zeiss, Oberkochen, Germany)
equipped with an argon laser emitting at 488 nm (yellow-green
Cy2-immunofluorescence) and a helium/neon laser emitting at
543 nm (red Cy3-immunofluorescence).
Quantification and statistical analysis
Changes in BSI-B4-IR were determined by densitometry (in
regions 1 and 2, Fig. 1a) using a digital image analyzer (Diana
II) in combination with an advanced image data analyzer
(AIDA 2.0). Results are expressed as percentage of the BSI-
B4-IR of the ACSF-treated sides in the same regions.
Additionally, the number of BSI-B4-labeled ramified and
activated microglial cells as well as GFAP and GFAP/BrdU
double-labeled cells were counted under a light microscope
(Axioskop; Zeiss) with a 20x objective within a square (0.5×
0.5 mm) in region 1 (Fig. 1a). Each value represents five
replications for each condition. The results were expressed as
a percentage of ACSF-treated sides of the same regions. The
individual groups were compared with one-way analysis of
variance (ANOVA) using Bonferroni t test. A probability level
of 0.05 or less was considered to be statistically significant.
Results
Immunocytochemistry
After mechanical injury (Fig. 1a,b), a characteristic BSI-B4
immunolabeling around the stab wound was observed in
comparison with untreated controls, decreasing in relation to
the distance from the lesion. In untreated rats, a great
number of resting (process-bearing) microglial cells was
present (Fig. 1d, arrows), whereas after stab-wound injury,
changes in the number of resting microglial cells with
retracted processes (Fig. 1e, arrow) and activated microglial
cells (Fig. 1f, arrowhead) were observed. Quantification of
BSI-B4-immunolabeling in the NAc (region 1; Fig. 1c) of
rats 4 days after stab-wound injury indicated a variable
influence of P2 receptor agonists on the number of activated
cells. Whereas α,βmeATP had no effect, 2MeSATP was
more potent in tendency than was ADPβS in increasing the
number of activated microglial cells. BzATP, which was
injected into the NAc in a higher dose than were the
previous ligands [28], also induced a marked enhancement
of activated microglial cells (Fig. 1c). UTPγS was without
effect, both on the number of activated microglia and on
resting microglia (not shown).
Quantification of BSI-B4-IR in the NAc (region 1 plus 2)
by densitometry showed a significant increase for all agonists
used with the exception of UTPγS (not shown) when com-
pared with ACSF-treated animals. The effects of α,βmeATP,
ADPβS, and 2MeSATP could be inhibited by pretreatment
with PPADS and those of BzATP by pretreatment with BBG
(Fig. 1g). PPADS and BBG given alone inhibited and failed
to alter BSI-B4-IR, respectively.
Double-immunofluorescence studies at P2X and P2Y
receptor subtypes
Multiple immunofluorescence labeling in combination with
laser scanning microscopy was used to characterize the P2X/
Yreceptorsubtypeexpressionafterinjuryincomparisonwith
untreated controls. Under control conditions, no P2X or P2Y
(with the exception of P2Y1) receptor-IR was coexpressed
on single GSA-B4-positive cells. The mechanical injury as-
sociated with the introduction of the injection cannula
resulted in the expression of P2X1,2,4,7 and P2Y1,2,4,6,12
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4 days after injury. An up-regulation of immunolabeling of
P2X1,2,4,7 receptor subtypes was unequivocal; examples are
shown in Fig. 2 (a–i). In the affected area, P2Y1,2 and P2Y12
fluorescence labeling was observed on GSA-B4-positive
cells with low intensity. P2Y4 labeling appeared preferen-
tially on process-bearing microglial cells (not shown).
P2X2-IR (Fig. 2c,d), P2X4 (Fig. 2e,f), and P2Y6-IR
(Fig. 2l,m) were found on both resting and especially on
activated microglial cells, the latter being identified by the
lack of processes. No immunofluorescence was observed for
P2X3,5,6 receptor subtypes on either type of microglial cells
before and after stab wounding.
Injury-induced prominent expression of the P2X7 receptor
was observed on microglial cells by double labeling with
GSA-B4 (Fig. 2g–i) and also on astrocytes, as described
earlier [29]. The two different P2X7 receptor antibodies, one
directed against the extracellular domain of the rat P2X7
receptor [25] and the other against its C terminus (C-terminal
P2X7) (Alomone Labs) labeled the same cells (Fig. 3a,b; thin
Fig. 1 a A rat brain slice
including needle tracts and
regions of interest within the
nucleus accumbens (NAc) in
which immunoreactivity (IR)
and cells were evaluated (1 core
1; 2 core 2; according to [29]).
b BSI-B4-marked microglial
cells after stab-wound injury
(overview). c Quantification
of the number of activated
microglial cells after injury and
microinjection of P2-receptor-
agonists 2MeSATP, ADPβS,
α,βmeATP (0.1 nmol each), and
BzATP (0.3 nmol) after a post-
injection time of 4 days. Values
are expressed as percentage of
ACSF-treated controls and
represent mean ± SEM of six
animals per group. d–f BSI-B4-
IR of microglial cells in the NAc
of rats, illustrating changes in
the glial morphology: d A great
number of resting (process-
bearing) microglial cells
(arrows) under control condi-
tions; e, f changes in the number
of resting microglial cells
(arrow) and activated microglial
cells (arrowhead)
after different treatment condi-
tions (scale bar=200 μm).
g Quantification of the effects of
agonists 2MeSATP, ADPβS,
α,βmeATP (0.1 nmol each), and
BzATP (0.3 nmol) alone and in
combination with PPADS
(0.1 nmol/0.03 nmol each) or
BBG (1 pmol) on BSI-B4-IR of
microglial cells in brain slices of
the NAc of the rat after a
postinjection time of 4 days.
Data are expressed as percent-
age of the ACSF-treated side
and represent the mean ± SEM
of six animals per group (*p<
0.05, vs. ACSF group; +p<0.05,
agonist vs. antagonist/agonist
group)
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examples of double immunoflu-
orescence labeling to character-
ize the colocalization of
P2X1,2,4,7 and P2Y1,6,12 receptor
subtypes on a–f OX42- or
g–o GSA-B4-labeled microglial
cells in the NAc of rats 4 days
after stab-wound injury (thin
arrow process-bearing micro-
glial cell; thick arrow activated
microglial cell) (scale bars:
a, b=20 μm; c, d=100 μm;
e–i=20 μm; j, k=100 μm;
l, m=20 μm; n, o=50 μm)
440 Purinergic Signalling (2007) 3:435–445arrow) but also different cells (Fig. 3c,d; thick arrow).
Additionally, the ecto-P2X7 antibody labeled GSA-positive
cells (data not shown).
Possible role of the P2X7 receptor after injury in vivo
To find out whether the P2X7 receptor is related to apoptotic
and/or proliferative processes after injury, we used the early
apoptotic marker active caspase 3 and the proliferation
marker BrdU. After BzATP microinjection, a significant
increase in the number of active caspase-3-positive cells was
found in comparison with ACSF-treated animals (Fig. 3k).
This effect was reduced by pretreatment with the P2X7
receptor antagonist BBG. Further, BBG given alone de-
creased the number of active caspase 3-immunopositive cells
in comparison with ACSF-treated rats (Fig. 3k).
Double immunofluorescence-labeling showed colocaliza-
tion of active caspase 3 at single GSA-B4-positive cells in the
NAc of rats (Fig. 3e,f). Furthermore, colocalization of the
ecto-P2X7 receptor subtype on caspase-3-positive cells was
also documented (Fig. 3g,h). Additionally, a possible co-
expression of the anti-apoptotic and possibly proliferation-
promoting pAkt on GSA-B4-positive cells was studied 4 days
after injury. However, no colocalization of pAkt with GSA-
B4-positive cells (Fig. 3i,j) was found by immunofluores-
cence labeling. Eventually, no colocalization of P2X7 and
pAkt was observed to this time point (data not shown).
A possible influence of P2X7 receptor stimulation on the
increase in cell number of activated and ramified microglial
cells after BzATP stimulation was also studied. Changes in
the number of activated microglia are shown in Fig. 1c. By
quantification of ramified (resting) microglial cells in region
1 (Fig. 1a), an increase to 123.8±5.3% in comparison with
ACSF-treated rats was found, similar to that after treatment
with 2MeSATP (124.0±7.8%). For comparison, no charac-
teristic changes were found after microinfusion of ADPβS
(108.3±11,6%) and α,βmeATP (101.7±6.9%). Besides the
effectsofBzATP on thenumberofactive andrestingmicroglial
cells, no influence of BzATP treatment on the number of GFAP
(specific marker for fibrous astrocytes)-positive cells (BzATP
1.7±7.3%; BBG 0.4±3.0%; BzATP/BBG 0.96±4.8%) was
found in comparison with ACSF-treated rats. There was alsono
Fig. 3 ApoptosisorproliferationafterP2X7 receptor stimulation after stab-
w o u n di n j u r yi nt h eN A co fr a t s4d a y sa f t e ri n j u r y .a–d Colocalization of
P2X7-IR detected by antibodies directed against the C-terminus (C-term)
(b, d) and the ectodomain (a–d)o ft h er a tP 2 X 7. e–j Confocal images of
double-labeling studies: Coexpression of active caspase 3 on single
GSA-B4-positive cells (e, f) and active caspase 3 and the ecto-P2X7
receptor subtype (g, h). No double labeling of pAkT on GSA-B4-
labeled microglial cells 4 days after injury (i, j) (scale bars: b–g=20μm).
k Quantification of the number of active caspase 3-positive cells in region
1( s e eF i g .1 a). Values are expressed as percentage of controls and
represent the mean ± SEM of six animals per group. (*p<0.05, vs. ACSF
group; +p<0.05,agonist vs. antagonist/agonist group; #p<0.05, antagonist
vs. antagonist/agonist group)
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liferatingcells)(BzATP14.8±4.5%;BBG8.8±11.2%;BzATP/
BBG 15.9±5.9%) in comparison with ACSF-treated rats.
Discussion
The results presented here demonstrate the involvement of
various P2 receptors in microglial response to the placement
of cannulas and microinjection, both resulting in tissue
damage and thereby in high extracellular ATP concentrations
[30]. Microglial cells stimulated by ATP may participate
both in neurodegeneration (apoptosis and/or necrosis) and
neuroprotection.
Cultured microglial cells from mouse or rat brain were
shown to respond to ATP with the activation of a cationic
conductance, accompanied by an increase in cytosolic Ca
2+
[8], followed by changes of microglial morphology [31, 32].
The exposition of cultured microglial cells to ADP or ATP
further induced membrane ruffling and markedly enhanced
chemokinesis, a prerequisite to perform tissue surveillance
in the brain [33].
In vivo, microglial cells are homogenously distributed
within the NAc characterized by rod-shaped somata with thin
and highly ramified processes extended in all directions.
Injurybystabwoundcausedmicroglialcellactivationaround
the lesion track, characterized by swollen somata and thicker
processes. The additional administration of P2X and P2Y
receptoragonistsenhancedtheoccurrenceofactivatedmicro-
glial cells detected by their BSI-IR. The observed changes
suggest that the stimulation of P2X1,3 receptors has only minor
relevance in the process of microglia activation, whereas in
agreement with the subsequent pharmacological investiga-
tions, involvement of P2X7 and P2Y1,2,4,6,12 receptors in this
process is highly probable.
Whereas P2X1–7 receptor-IR was absent in the non-
affected NAc, the expression of P2X1,2,3,4,7 receptors but not
of P2X5,6 receptors was detected after the stab-wound
lesion. P2X2,4,6 receptors are widely expressed in central
and peripheral neurones as well as other excitable cells [22,
34, 35], and the P2X7 receptor is expressed in macrophage-
type cells such as microglia but also mediates purinergic
responses in astrocytes and neurons [36]. Changes in micro-
glial expression of P2X receptors (P2X1–7) during postnatal
development of the rat have been described [37]. Obviously,
microglial cells are involved in long-term trophic events
such as cell proliferation, differentiation, movement, and
death during development [37].
Upregulation of P2X1-IR at microglial cells, as found in
this study, was described at activated astrocytes after stab-
wound injury in the adult rat NAc [29]. Further, the P2X2
receptor was found to be situated at activated microglia in
our study and previously at astroglial cells [29]. After is-
chemia in vivo, P2X2 and P2X4-receptor-IR in the hippo-
campus became up-regulated in different cellular phenotypes
[38]. P2X2 was expressed on neuronal cell bodies and fibers
in hippocampal pyramidal cells, whereas intensive P2X4-IR
was localized at microglial cells. Confocal microscopic anal-
ysis with OX 42 [39] at organotypic cultures showed that
P2X4 and P2X7 are expressed on microglia, whereas P2X1
and P2Y1,2,12, although present in the slices, do not colo-
calize at microglia, and the P2X6 receptor is absent. P2X4
receptors seem to be functionally relevant for microglial
chemotaxis, which was suppressed by the knockdown of the
P2X4 receptor in cultured microglia by ribonucleic acid
(RNA) interference through the lentivirus vector system [33].
After spinal-nerve injury, P2X4 receptor expression strik-
ingly increased at the ipsilateral site in hyperactive microglia
but not in neurons or astrocytes [40]. Intraspinal adminis-
tration of P2X4 receptor antisense oligodeoxynucleotide de-
creased induction of P2X4 receptors and suppressed tactile
allodynia after nerve injury.
ThemajorP2Xreceptorexpressedatmicroglialcellsisthe
P2X7 receptor, characterized in several reports in vitro [13,
16, 41]. This receptor subtype appeared to be strongly
coexpressed with the microglial marker GSA-B4 after the
mechanical lesion used in our study, suggesting an out-
standing role of this receptor in injury-induced microglial
responses. It is thought to be closely related to the immune
functions of microglia, such as production of inflammatory
cytokines, superoxide, and nitric oxide [42]. The P2X7
receptor is reported to be little susceptible to desensitization in
the presence of ATP, which makes it quite different from other
purinergic receptors, including the P2X4 receptor, which can be
desensitized within a few minutes [23, 43]. Up-regulation of
microglial P2X7 receptors has been observed in several path-
ological models, such as in vivo ischemia [41, 44, 45], as well
as multiple sclerosis and amyotrophic lateral sclerosis of the
human spinal cord [46]. The P2X7 receptors were also spe-
cifically up-regulated around β-amyloid plaques in a mouse
model of Alzheimer’s disease (Tg2576) [47] and in human
proliferative vitreoretinopathy on Müller glial cells [48].
Within the P2Y receptor family, in our study, the P2Y1
receptor was markedly expressed on microglial cells of un-
treated rats and was up-regulated in concert with P2Y2,4,6,12
receptors after injury. In the rabbit retina, microglial cells
express functional P2Y1 receptors [49]. Activation of these
receptors stimulates phenotypic alterations characteristically
for microglial activation.
Our data also demonstrate a strong colocalization of the
P2Y6 receptor with GSA-IR. In addition to the microglial
function to build a barrier between injured and healthy
tissue, these cells are able to clear dead cells or dangerous
debris from brain tissue. This phagocytotic process was
shown to be triggered by activation of P2Y6 receptors by the
endogenous agonist UDP [50].
442 Purinergic Signalling (2007) 3:435–445Several authors report on ATP-induced migration of
microglial cells to the affected sites of the brain [9, 10, 51–
53]. Expression of the P2Y12 receptor on microglial cells
after injury seems to be strongly related to the motility of this
cell type. In primary cultured microglial cells, exposition to
ADP or ATP induced membrane ruffling and markedly
enhanced chemokinesis, which could be blocked by the
P2Y12 receptor antagonist cangrelor (AR-C69931MX), sug-
gesting that Gi/o-coupled P2Y receptors are involved [10].
The high dynamic of intact microglial processes as well as
their chemotactic response to injury or local injection of ATP
was shown in mouse cortex using time-lapse, two-photon
laser imaging [9]. Investigations in P2Y12 receptor-deficient
mice gave further support that P2Y12 receptors are required
for the nucleotide-evoked chemotaxis [33, 54]. Eventually,
expression of P2Y12 receptors was observed in native and
axotomized facial nuclei, and the number of P2Y12-express-
ing cells increased following facial nerve axotomy, consid-
ered to be a crucial component in the regeneration cascades
of motor neurons [55].
The published data confirm that not all known P2 recep-
tors can be detected by their immunoreactivity. However, the
mRNA of the P2X1–7 [29] and P2Y1,2,4,6,12 subtypes [27]
was detectable in the NAc of untreated rats. The P2
receptors present on microglia may be differently involved
in the processes of their activation, as shown by the inhi-
bition of BSI-B4-IR using PPADS and BBG. It can be
suggested by pharmacological studies that P2Y1 and P2X7
receptors may play a predominant role in the response of
microglia to the consequences of a stab wound in the NAc.
Retinal detachment and application of ADPßS onto
control retinas induced phenotype alterations of microglial
cells (decrease of soma size, retraction of cell processes) and
had no influence on microglial cell density [49]. In the stab-
wound model, stimulation of P2 receptors with agonists
preferring P2Y1 and P2X7 receptor subtypes promoted the
morphological changes of resting to activated microglial
cells.
P2X7 receptors are ATP-gated ion channels; their sus-
tained activation leads to cytolysis in an apoptotic fashion in
the microglia [56]. P2X7 receptor-mediated apoptosis
involves activation of the proteolytic pathway of caspase
activation, which leads to nuclear DNA damage [57]. In our
study, immunocytochemistry showed expression of P2X7
and active caspase 3 at GSA-positive cells after injury with-
out agonist application. The active caspase 3 has been
defined as the main executioner of programmed cell death
and as an early apoptotic marker [58]. The microinfusion of
BzATP increased the number of caspase-3-positive cells,
suggesting an involvement of P2X7 receptors in apoptotic
changes after traumatic events. The BzATP-induced increase
in ramified and activated microglia (and proliferating as-
trocytes) was only marginal.
The phosphoinositide-3-kinase/serine-threonine-kinase
Akt (PI3-K/Akt) pathway is associated with cell prolifera-
tion, promoting cell survival and inhibiting apoptosis [59].
Because in the present study performed at 4 days after
injury no coexpression of pAkt with GSA and P2X7 was
found, the evidence for a preferential apoptotic pathway
triggered by P2X7 receptors is unlikely.
Up-regulation of P2 receptors after mechanical injury
might be both the cause and the result of the induction of
apoptotic/necrotic cell death activating microglial cells with
harmful or beneficial effects. The present results from in vivo
investigations implicate that ATP via both P2X and P2Y
receptor-stimulation acts as a signaling molecule in micro-
glial cells in vivo. An up-regulation of P2X7-IR after injury
suggests involvement of this receptor subtype in apoptotic
rather than in proliferative events.
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